Literature DB >> 3014034

Immunization with SV40-transformed cells yields mainly MHC-restricted monoclonal antibodies.

B G Froscher, N R Klinman.   

Abstract

Recognition of antigens on cell surfaces only in the context of the MHC-encoded alloantigens of the presenting cell (self + X) has classically been considered the province of T cells. However, evidence from several sources has indicated that B cells and antibodies can exhibit self + X-restricted recognition as well. This report concerns the mAb response to SV40-transformed H-2b fibroblast cell lines. The specificities of the antibodies obtained have been analyzed for binding to a panel of SV40-transformed H-2-syngeneic, H-2-allogeneic, and H-2b mutant fibroblast cell lines, as well as cell lines not bearing cell surface SV40 transformation-associated antigens. A large proportion of primary C57BL/6 (71%) and BALB/c (68%) splenic B cells responding to in vitro stimulation with SV40-transformed H-2b cells recognize cell surface antigens associated with SV40 transformation only when coexpressed with MHC antigens of the immunizing cell, particularly the Kb molecule, on transformed cells. To extensively define the nature of antigen recognition by these antibodies, we have generated and characterized nine hybridoma antibodies specific for SV40-transformed H-2-syngeneic cell lines. Seven of these hybridoma antibodies recognize SV40-associated transformation antigens in the context of H-2b molecules. Six of these are restricted by the Kb molecule and discriminate among a panel of SV40-transformed Kb mutant cell lines, thus confirming the participation of class I MHC-encoded molecules in the recognition by B cells of cell surface antigens.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3014034      PMCID: PMC2188216          DOI: 10.1084/jem.164.1.196

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  44 in total

Review 1.  The atomic mobility component of protein antigenicity.

Authors:  J A Tainer; E D Getzoff; Y Paterson; A J Olson; R A Lerner
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

2.  Interaction of monoclonal anti-peptide antibodies with lysozyme.

Authors:  A Hirayama; Y Takagaki; F Karush
Journal:  J Immunol       Date:  1985-05       Impact factor: 5.422

3.  Binding of immunogenic peptides to Ia histocompatibility molecules.

Authors:  B P Babbitt; P M Allen; G Matsueda; E Haber; E R Unanue
Journal:  Nature       Date:  1985 Sep 26-Oct 2       Impact factor: 49.962

4.  Three-dimensional structure of an antigen-antibody complex at 6 A resolution.

Authors:  A G Amit; R A Mariuzza; S E Phillips; R J Poljak
Journal:  Nature       Date:  1985 Jan 10-18       Impact factor: 49.962

5.  Recognition by cytotoxic T lymphocytes of cells expressing fragments of the SV40 tumor antigen.

Authors:  L R Gooding; K A O'Connell
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

6.  B cell repertoire diversification precedes immunoglobulin receptor expression.

Authors:  R L Riley; D E Wylie; N R Klinman
Journal:  J Exp Med       Date:  1983-11-01       Impact factor: 14.307

7.  Role of variable region gene expression and environmental selection in determining the antiphosphorylcholine B cell repertoire.

Authors:  N R Klinman; M R Stone
Journal:  J Exp Med       Date:  1983-12-01       Impact factor: 14.307

8.  Selective modification of a private I-A allo-stimulating determinant(s) upon association of antigen with an antigen-presenting cell.

Authors:  K L Rock; B Benacerraf
Journal:  J Exp Med       Date:  1984-04-01       Impact factor: 14.307

9.  Antigen responsiveness of the mature and generative B cell populations of aged mice.

Authors:  D Zharhary; N R Klinman
Journal:  J Exp Med       Date:  1983-04-01       Impact factor: 14.307

10.  Genetic and temporal control of neonatal antibody expression.

Authors:  K A Denis; N R Klinman
Journal:  J Exp Med       Date:  1983-04-01       Impact factor: 14.307

View more
  11 in total

1.  A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.

Authors:  P S Andersen; A Stryhn; B E Hansen; L Fugger; J Engberg; S Buus
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

Review 2.  TCR-like biomolecules target peptide/MHC Class I complexes on the surface of infected and cancerous cells.

Authors:  Jon A Weidanz; Oriana Hawkins; Bhavna Verma; William H Hildebrand
Journal:  Int Rev Immunol       Date:  2011 Oct-Dec       Impact factor: 5.311

3.  Alloantibodies can discriminate class I major histocompatibility complex molecules associated with various endogenous peptides.

Authors:  L A Sherman; S Chattopadhyay; J A Biggs; R F Dick; J A Bluestone
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

4.  Immunization with syngeneic Sendai virus-infected cells induce no MHC-restricted antibodies but antibodies specific for H-2 class I determinants.

Authors:  F Kievits; W J Boerenkamp; P Ivanyi
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

5.  H-2-specific antibodies induced by injection of syngeneic leukemia cells.

Authors:  W Schmidt
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

6.  Analysis of the expression of peptide-major histocompatibility complexes using high affinity soluble divalent T cell receptors.

Authors:  S M O'Herrin; M S Lebowitz; J G Bieler; B K al-Ramadi; U Utz; A L Bothwell; J P Schneck
Journal:  J Exp Med       Date:  1997-10-20       Impact factor: 14.307

7.  T cell receptor-like recognition of tumor in vivo by synthetic antibody fragment.

Authors:  Keith R Miller; Akiko Koide; Brenda Leung; Jonathan Fitzsimmons; Bryan Yoder; Hong Yuan; Michael Jay; Sachdev S Sidhu; Shohei Koide; Edward J Collins
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

8.  Monoclonal antibodies against viral determinants are not restricted to the K/D end of the major histocompatibility complex.

Authors:  B Pestalozzi; L Stitz; R M Zinkernagel
Journal:  J Exp Med       Date:  1987-07-01       Impact factor: 14.307

9.  Major histocompatibility complex conformational epitopes are peptide specific.

Authors:  B Catipović; J Dal Porto; M Mage; T E Johansen; J P Schneck
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

Review 10.  TCR-like antibodies in cancer immunotherapy.

Authors:  Qinghua He; Zhaoyu Liu; Zhihua Liu; Yuxiong Lai; Xinke Zhou; Jinsheng Weng
Journal:  J Hematol Oncol       Date:  2019-09-14       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.